title: CD133+ cell content does not influence recovery time after hematopoietic stem cell transplantation.
abstract: BACKGROUND
  Infusion of an adequate dose of CD34+ mononuclear hematopoietic stem cells (HSCs) is the single most important variable to assure success in hematopoietic grafting. CD133+ HSCs constitute the CD34+ subgroup with higher differentiation potential. The number of granulocyte-colony-stimulating factor (G-CSF)-mobilized CD133+ HSCs administered during hematopoietic grafting and its relationship with the number of days needed to regain hematopoiesis was determined.
  
  
  METHODS
  Thirty-eight patients with malignant hematologic diseases who received an autologous (n = 15) or allogeneic (n = 23) HSC transplant were prospectively evaluated. G-CSF was administered for 5 days at 10 microg/kg/day. Hematopoietic progenitors were recovered from peripheral blood on day 5 by leukopheresis. CD34+ and CD133+/CD34+ cell populations were quantified by flow cytometry; the number of days to hematologic recovery was documented.
  
  
  RESULTS
  A median dose of 4.56 x 10(6)/kg CD34+ HSCs (range, 1.35 x 10(6)-14.6 x 10(6)) was recovered and transplanted; of these grafted cells, a median 3.25 x 10(6) were also CD133+ (range, 1.25 x 10(6)-14.3 x 10(6)). In the autologous group, the median number of days to reach a platelet (PLT) count of 20 x 10(9)/L or greater was 12, and 15 days to obtain a neutrophil count of 0.5 x 10(9)/L or greater; in the allogeneic group 13 and 16 days, respectively, were required (p > 0.05). A median 76.5% of G-CSF-mobilized CD34+ HSCs coexpressed the CD133+ antigen (range, 23.1-97.9).
  
  
  CONCLUSIONS
  A higher number of CD133+/CD34+ HSCs in the graft was not clearly associated with a shorter neutrophil or PLT recovery time in either allogeneic or autologous recipients.
authors.affiliation: Servicio de Hematología, Hospital Universitario Dr José E. González, Facultad de Medicina de la Universidad Autónoma Nuevo León, Monterrey, NL, México. carjaime@hotmail.com
authors.forename: José Carlos
authors.initials: JC
authors.lastname: Jaime-Pérez
authors.forename: Víctor A
authors.initials: VA
authors.lastname: Guillermo-Villanueva
authors.forename: Nereida
authors.initials: N
authors.lastname: Méndez-Ramírez
authors.forename: Adrián
authors.initials: A
authors.lastname: Chapa-Rodríguez
authors.forename: Homero
authors.initials: H
authors.lastname: Gutiérrez-Aguirre
authors.forename: David
authors.initials: D
authors.lastname: Gómez-Almaguer
mesh_terms: D000071916:AC133 Antigen; D015703:Antigens, CD / Q000378:metabolism*; D018952:Antigens, CD34 / Q000378:metabolism; D006023:Glycoproteins / Q000378:metabolism*; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology; D019337:Hematologic Neoplasms / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006412:Hematopoietic Stem Cells / Q000187:drug effects / Q000378:metabolism; D010455:Peptides / Q000378:metabolism*; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
chemical_list: D000071916:AC133 Antigen; D015703:Antigens, CD; D018952:Antigens, CD34; D006023:Glycoproteins; D010455:Peptides; D016179:Granulocyte Colony-Stimulating Factor